NCT05433506View on ClinicalTrials.gov

Safety and Pharmacokinetics of HU6

PHASE1CompletedINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

September 15, 2022

Primary Completion Date

January 30, 2023

Study Completion Date

March 15, 2023

Conditions

Obese

Interventions

DRUG

HU6 Tablet

Six subjects will receive a tablet formulation.

DRUG

HU6 Capsule

Six subjects will receive the capsule formulation

Trial Locations (1)

55114

Nucleus Network, Minneapolis

All Listed Sponsors

lead

Rivus Pharmaceuticals, Inc.

INDUSTRY